Focused On-demand Library for Interleukin-18 receptor accessory protein

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

O95256

UPID:

I18RA_HUMAN

Alternative names:

Accessory protein-like; CD218 antigen-like family member B; CDw218b; IL-1R accessory protein-like; Interleukin-1 receptor 7; Interleukin-18 receptor accessory protein-like; Interleukin-18 receptor beta

Alternative UPACC:

O95256; B2RPJ3; Q2QDE5; Q3KPE7; Q3KPE8; Q53TT4; Q53TU5

Background:

The Interleukin-18 receptor accessory protein, known by alternative names such as Accessory protein-like and IL-1R accessory protein-like, plays a crucial role in immune response regulation. It is part of the IL18 receptor complex, facilitating IL18-dependent signal transduction, which activates NF-kappa-B and JNK. This protein is instrumental in IFNG synthesis from T-helper 1 cells, highlighting its significance in immune system functionality.

Therapeutic significance:

Understanding the role of Interleukin-18 receptor accessory protein could open doors to potential therapeutic strategies. Its involvement in key immune response pathways suggests its potential as a target for modulating immune responses in various conditions.